2026 Q2 - tulosraportti
57 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 729 | ||
| 5 000 | ||
| 1 496 | ||
| 1 000 | ||
| 1 867 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenAnalyst group kom med sin analyse kl 16:42 ". The advantage therefore carries over, addressing the question Analyst Group identified in its H1-26 analysis as outstanding, though these remain initial results generated with circVec 3.2. Reporter expression in heart has since risen from approx. 40x with that construct to approx. 200x with circVec 5.2, and Analyst Group would expect the therapeutic-protein data to improve as the newer designs are applied." In summary, Analyst Group views the ESGCT materials as adding precision to the platform’s characterization alongside the step up in heart expression, with the cardiac specificity the most important addition. What remains open is whether the additional protein makes diseased animals better, which the in vivo heart disease-model studies are designed to establish https://analystgroup.se/bolag/circio-holding/analyst-group-comment-on-circios-esgct-presentations-and-the-new-circvec-5-2-heart-design .Circio expects those studies to begin in Q1-27, with read-outs during the year, in line with the six-to-twelve-month guidance given in September, while the R&D webcast at the end of November, presenting in vivo heart and eye results expected to complete during the month, is the nearer-term test.
#Jens's favorite tax #driving the country into the ditch And those of you who don't pay wealth tax can just refrain from commenting, because you don't know what you're talking about......- ·2 t sittenGrotesquely oversold after today's news and latest two technological updates. ( 1. sep and today) Down from 15.7 kr the last two months is insane. Market cap for a leading gene therapy company at barely 3 bln is unbelievable.Has probably been a share issue here too after we were at 15.7, the second in a row at that...
- ·2 t sittenFigure 5 shows fantastic improvements and a potential technological breakthrough with circVec5.2 Compared to circVec3.2, the proportion of the measured signal from the heart increases from approx. 65 % to a full 94 % with circVec5.2, while the proportion from the liver is reduced from approx. 4 % to under 1 %. I.e. circVec5.2 provides approximately 45 % higher heart signal proportion and over 75 % lower liver signal proportion than circVec3.2. In addition, the figure shows up to 5 times improved translation, and a full 163 times higher luminescence in the heart compared to mVec.
·3 t sitten · MuokattuSolid product development and progress are clearly not synonymous with cheering in the stock market. CircVec 5 variant with huge specification at its heart is a brilliant news, but this resembles too much what the market has received in previous variants 3 and 4. It does not feel like new even though it of course is and has required significant development effort. What the market probably hoped for was more groundbreaking news in CAR-T. That cannot be said to have come and I think much of today's reaction came from here. CAR-T project is dependent on the perfect delivery technology. Here Circio depends on its partners and this may indicate that since several of these first came this spring, time is needed. It is completely critical that Circio at this point does not choose wrong. There have been massive cancellations and failure of studies in various CAR-T projects also among big pharma over the last half year. Probably because they have been too quick out and based on unsatisfactory technologies. They have to find something new and better. It is therefore understandable that this is quality assured and checked in several ways. Despite circVec 5 the market probably perceived this as status quo and not enough for a short-term trigger. The Circio project has progressed and is more solid than ever. Today's news probably also strengthens the CNS project with big pharma. No reason for concern but allowed to be a little bummed because the short-term trigger did not come now. After all, a presentation at a scientific conference. Personally, I think it is in the cards that a new deal will soon come because this is noticed in the biotech industry. They have been traveling a lot since September 1. We will see. No reason to lose sleep.
I think you overestimate the market, today it has only been about traiding, 90% of the short-term investors here have not read or understand the news, just to ignore the share price, and be happy about yet another step forward in the fundamental bank.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
57 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenAnalyst group kom med sin analyse kl 16:42 ". The advantage therefore carries over, addressing the question Analyst Group identified in its H1-26 analysis as outstanding, though these remain initial results generated with circVec 3.2. Reporter expression in heart has since risen from approx. 40x with that construct to approx. 200x with circVec 5.2, and Analyst Group would expect the therapeutic-protein data to improve as the newer designs are applied." In summary, Analyst Group views the ESGCT materials as adding precision to the platform’s characterization alongside the step up in heart expression, with the cardiac specificity the most important addition. What remains open is whether the additional protein makes diseased animals better, which the in vivo heart disease-model studies are designed to establish https://analystgroup.se/bolag/circio-holding/analyst-group-comment-on-circios-esgct-presentations-and-the-new-circvec-5-2-heart-design .Circio expects those studies to begin in Q1-27, with read-outs during the year, in line with the six-to-twelve-month guidance given in September, while the R&D webcast at the end of November, presenting in vivo heart and eye results expected to complete during the month, is the nearer-term test.#Jens's favorite tax #driving the country into the ditch And those of you who don't pay wealth tax can just refrain from commenting, because you don't know what you're talking about......
- ·2 t sittenGrotesquely oversold after today's news and latest two technological updates. ( 1. sep and today) Down from 15.7 kr the last two months is insane. Market cap for a leading gene therapy company at barely 3 bln is unbelievable.Has probably been a share issue here too after we were at 15.7, the second in a row at that...
- ·2 t sittenFigure 5 shows fantastic improvements and a potential technological breakthrough with circVec5.2 Compared to circVec3.2, the proportion of the measured signal from the heart increases from approx. 65 % to a full 94 % with circVec5.2, while the proportion from the liver is reduced from approx. 4 % to under 1 %. I.e. circVec5.2 provides approximately 45 % higher heart signal proportion and over 75 % lower liver signal proportion than circVec3.2. In addition, the figure shows up to 5 times improved translation, and a full 163 times higher luminescence in the heart compared to mVec.
- ·3 t sitten · MuokattuSolid product development and progress are clearly not synonymous with cheering in the stock market. CircVec 5 variant with huge specification at its heart is a brilliant news, but this resembles too much what the market has received in previous variants 3 and 4. It does not feel like new even though it of course is and has required significant development effort. What the market probably hoped for was more groundbreaking news in CAR-T. That cannot be said to have come and I think much of today's reaction came from here. CAR-T project is dependent on the perfect delivery technology. Here Circio depends on its partners and this may indicate that since several of these first came this spring, time is needed. It is completely critical that Circio at this point does not choose wrong. There have been massive cancellations and failure of studies in various CAR-T projects also among big pharma over the last half year. Probably because they have been too quick out and based on unsatisfactory technologies. They have to find something new and better. It is therefore understandable that this is quality assured and checked in several ways. Despite circVec 5 the market probably perceived this as status quo and not enough for a short-term trigger. The Circio project has progressed and is more solid than ever. Today's news probably also strengthens the CNS project with big pharma. No reason for concern but allowed to be a little bummed because the short-term trigger did not come now. After all, a presentation at a scientific conference. Personally, I think it is in the cards that a new deal will soon come because this is noticed in the biotech industry. They have been traveling a lot since September 1. We will see. No reason to lose sleep.I think you overestimate the market, today it has only been about traiding, 90% of the short-term investors here have not read or understand the news, just to ignore the share price, and be happy about yet another step forward in the fundamental bank.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 729 | ||
| 5 000 | ||
| 1 496 | ||
| 1 000 | ||
| 1 867 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
57 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenAnalyst group kom med sin analyse kl 16:42 ". The advantage therefore carries over, addressing the question Analyst Group identified in its H1-26 analysis as outstanding, though these remain initial results generated with circVec 3.2. Reporter expression in heart has since risen from approx. 40x with that construct to approx. 200x with circVec 5.2, and Analyst Group would expect the therapeutic-protein data to improve as the newer designs are applied." In summary, Analyst Group views the ESGCT materials as adding precision to the platform’s characterization alongside the step up in heart expression, with the cardiac specificity the most important addition. What remains open is whether the additional protein makes diseased animals better, which the in vivo heart disease-model studies are designed to establish https://analystgroup.se/bolag/circio-holding/analyst-group-comment-on-circios-esgct-presentations-and-the-new-circvec-5-2-heart-design .Circio expects those studies to begin in Q1-27, with read-outs during the year, in line with the six-to-twelve-month guidance given in September, while the R&D webcast at the end of November, presenting in vivo heart and eye results expected to complete during the month, is the nearer-term test.#Jens's favorite tax #driving the country into the ditch And those of you who don't pay wealth tax can just refrain from commenting, because you don't know what you're talking about......
- ·2 t sittenGrotesquely oversold after today's news and latest two technological updates. ( 1. sep and today) Down from 15.7 kr the last two months is insane. Market cap for a leading gene therapy company at barely 3 bln is unbelievable.Has probably been a share issue here too after we were at 15.7, the second in a row at that...
- ·2 t sittenFigure 5 shows fantastic improvements and a potential technological breakthrough with circVec5.2 Compared to circVec3.2, the proportion of the measured signal from the heart increases from approx. 65 % to a full 94 % with circVec5.2, while the proportion from the liver is reduced from approx. 4 % to under 1 %. I.e. circVec5.2 provides approximately 45 % higher heart signal proportion and over 75 % lower liver signal proportion than circVec3.2. In addition, the figure shows up to 5 times improved translation, and a full 163 times higher luminescence in the heart compared to mVec.
- ·3 t sitten · MuokattuSolid product development and progress are clearly not synonymous with cheering in the stock market. CircVec 5 variant with huge specification at its heart is a brilliant news, but this resembles too much what the market has received in previous variants 3 and 4. It does not feel like new even though it of course is and has required significant development effort. What the market probably hoped for was more groundbreaking news in CAR-T. That cannot be said to have come and I think much of today's reaction came from here. CAR-T project is dependent on the perfect delivery technology. Here Circio depends on its partners and this may indicate that since several of these first came this spring, time is needed. It is completely critical that Circio at this point does not choose wrong. There have been massive cancellations and failure of studies in various CAR-T projects also among big pharma over the last half year. Probably because they have been too quick out and based on unsatisfactory technologies. They have to find something new and better. It is therefore understandable that this is quality assured and checked in several ways. Despite circVec 5 the market probably perceived this as status quo and not enough for a short-term trigger. The Circio project has progressed and is more solid than ever. Today's news probably also strengthens the CNS project with big pharma. No reason for concern but allowed to be a little bummed because the short-term trigger did not come now. After all, a presentation at a scientific conference. Personally, I think it is in the cards that a new deal will soon come because this is noticed in the biotech industry. They have been traveling a lot since September 1. We will see. No reason to lose sleep.I think you overestimate the market, today it has only been about traiding, 90% of the short-term investors here have not read or understand the news, just to ignore the share price, and be happy about yet another step forward in the fundamental bank.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 729 | ||
| 5 000 | ||
| 1 496 | ||
| 1 000 | ||
| 1 867 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt